Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + Melphalan + Dexamethasone in AL-Amyloidosis
NCT00621400Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Jan 2008
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in amyloid light chain amyloidosis, sponsored by CHU de Nantes. Primary endpoint: Maximum Tolerated Dose. Started Jan 2008; status: completed.
02
Drugs
lenalidomide
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT00621400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00621400.